Showing posts with label Inc. (NasdaqGS: EXEL) and Peregrine Pharmaceuticals. Show all posts
Showing posts with label Inc. (NasdaqGS: EXEL) and Peregrine Pharmaceuticals. Show all posts

Thursday, May 28, 2009

Biotech/Pharma Stocks Sector Close- Up; Exelixis, Inc. (NasdaqGS: EXEL) and Peregrine Pharmaceuticals, Inc. (NasdaqCM: PPHM) Give Investors and Traders Big Gains

POINT ROBERTS, Wash., May 28, 2009 http://www.biotechindustrystocks.com/, a global investor website for the biotechnology sector within Investorideas.com, presents a biotech stocks sector close- up following sharp gains from Exelixis, Inc.(NasdaqGS: EXEL) and Peregrine Pharmaceuticals, Inc. (NasdaqCM: PPHM) trading at $ 1.07, up $0.47 (78.33%).

Biotech stocks have shown investors that this is a sector to watch in 2009.

Biotech Stock News - Exelixis (NASDAQ:EXEL) and Sanofi-aventis Sign Global License Agreement for XL147 & XL765 and Launch Broad Collaboration for Discovery of PI3K Inhibitors

Biotech/Pharma Stocks Sector Close –Up Trading May 28, 2009
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) trading at $ 2.1, up $ 0.41 (23.84%) 12:17pm ET, with a high of $2.58
Exelixis, Inc. (NasdaqGS: EXEL) trading at $5.50, up $0.99 (21.95%) 12:16pm ET, with a day high of $ $6.10
Peregrine Pharmaceuticals, Inc. (NasdaqCM: PPHM) trading at $ 1.07, up $0.47 (78.33%) 12:19pm ET

Company Snapshot:

Exelixis, Inc. (NasdaqGS: EXEL) is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo.
Submit Biotech company profiles: http://www.investorideas.com/Profile/Submission.asp

The global Biotech Stocks Directory at Biotechindustrystocks.com and Investorideas.com features a directory of Medical Stocks, Life Sciences and Pharma Stocks for investors to research.

Visit the Biotech/Pharma Stock Directory: http://www.investorideas.com/Research/Biotech,PharmaStocks.asp

Biotech public and private companies can submit news releases at: http://www1.investorideas.com/NewsUploader/Default.aspx
Biotech Showcase companies: http://www.investorideas.com/About/companies.asp

About Biotechindustrystocks.com:
BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech sector, within Investorideas.com. Global visitors use the site daily to research the latest biotech stock and industry news, articles, audio, research reports and our stock directories.

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.

Investorideas.com Membership – Access full Biotech Stocks Directory, water stocks and more…
With markets and investor sentiment changing daily- it is more important than ever to stay on top of key trends! Gain Exclusive Insight on Leading Sectors, Global Trends, and Insider Trading Ideas, News, Articles and Investor Ideas Members only Restricted Content including the complete renewable energy stocks directory, water stocks, biotech and defense stocks directory, as well as the Insiders Corner by Michael Brush.
Become an InvestorIdeas.com -Learn more: http://www.investorideas.com/membership/

InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp
Our sites do not make recommendations, but offer information portals to investors to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of any information presented. All information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is compensated by featured companies, news submissions and online advertising.

For more information contact:
Dawn Van Zant 800.665.0411 dvanzant@investorideas.com
Or cvanzant@investorideas.com